One page per compound, built from the same reference data the TherapyLog app runs on — the modelled half-life, the storage rule, the monitoring panel, the documented interactions — with the pharmacology written out rather than summarised into a benefits list.
81 pages so far. Type to filter, or press Enter to jump straight to the first match. Each heading below is a link you can share on its own — /compounds/#growth-hormone opens this page at that group.
The esters and the routes, the two oral androgens that act on binding rather than on the receptor, and the one hormone here that is usually prescribed alongside oestrogen. Everything androgenic in this group suppresses your own production.
Aromatase inhibitors, the receptor modulators, and the compounds that act on the pituitary or the testis directly. The failure mode across most of this group is over-correction, and it looks like the problem it was meant to fix.
The prohormone, the active hormone, and the porcine extract that supplies both in a ratio you cannot change. Which value to read differs between them.
The incretin drugs and what is behind them in trials, the older metabolic compounds people combine with them, the hormone all of this is ultimately about, and one research compound with no human data at all.
Humulin R, Novolin R, regular human insulin, insulin lispro, aspart, glargine
Approved or OTCGrowth hormone itself, the releasing-hormone analogues, the ghrelin receptor agonists and the fragments, plus the myostatin pathway. IGF-1 is the marker for most of them, and it measures exposure rather than benefit.
Somatropin, rHGH, Human Growth Hormone, Genotropin, Norditropin, Humatrope, Omnitrope, Somatropin (rhGH)
Approved or OTCThe healing peptides, the immune peptides and the gut barrier compounds. Also the group with the widest gap between how confidently these are described and what has actually been tested in people.
Compounds taken on mechanism and animal lifespan data. None of them has a human longevity outcome, because no such trial has run long enough to have one.
Mostly compounds approved in one country and unstudied everywhere else, with subjective endpoints and no bloodwork to anchor them.
The melanocortin agonists — one selective and approved for one indication, one that activates the whole receptor family and changes every mole on the body — alongside the skin compounds and the bonding hormone.
Copper Peptide, Glycyl-L-Histidyl-L-Lysine, GHK-Copper, GHK-Cu (Copper Peptide)
Approved or OTCAvailable without a prescription, which is a statement about regulation rather than about how carefully they need to be used.
Every fact in the boxes on a compound page is lifted from the app at build time: the half-life and time to peak, the formulation, the storage rule and its handling caveat, the monitoring panel, the drawbacks the app records, the dosing rows it holds, and the interaction rules that name the compound. That means these pages cannot quietly disagree with the app, and a change to the app's reference shows up here on the next build rather than never.
What they are not is a protocol. No page here tells a reader to take an amount, and none of them reproduces the app's combination protocols — a combination presented as a plan under a byline is a recommendation to run it, whatever the disclaimer underneath says. The combination checker covers combinations from the other direction, as a check for documented conflicts. There is no vendor, clinic, testing service or discount code on any of these pages, and there will not be.
Each page also publishes the drawbacks the app records and not the benefits it records. That asymmetry is deliberate. A risk someone has not heard of is worth reading; a list of benefits under the founder's byline on a page built to rank is advertising, and labelling it otherwise would not change what it is.
The app's reference covers 131 compounds. 108 of them can be described responsibly on a public page, and they are split into two groups that are presented differently:
The remaining 23 are in the app and do not get a page here. They are the anabolic-androgenic steroids and selective androgen receptor modulators used for performance, and the reasoning is not squeamishness: a page about them under this byline, written to rank, would function as promotion no matter how it was framed, and the honest version of that page is one nobody would publish. They stay in the app, where they exist to make a log accurate for someone already using them, and off the indexable site.
81 of the 108 publishable compounds have a page so far; the others are being written in batches, and nothing is linked here until its page is live and has been read end to end. In the meantime the app's own encyclopedia carries all 131 with the same underlying data — open it here, no account needed. The calculators cover reconstitution, syringe volumes and half-life arithmetic, and the lab-marker pages cover the bloodwork that follows most of these.
The app holds the same reference data these pages are built from, plus the log that turns a dose and a lab result into a trend.
Open the referenceThis calculator does the arithmetic you typed and nothing else. It does not know what is actually in your vial, whether the label is accurate, or anything about you. Confirm the vial strength and the diluent volume on your own label before you draw, and take dosing decisions to a qualified provider.